Our non-HLA matched therapies target hematopoietic recovery, chemotherapy induced neutropenia and are being extended to treat a range of other medical indications.
The science behind umbilical cord blood transplants
See how researchers are making the leap from basic science to new treatments.
Hematopoietic Stem/Progenitor Cell Expansion
During hematopoietic development, the progeny of pluripotent stem cells progressively lose their proliferative potential and capacity for self-renewal, and display greater commitment to a given differentiation pathway.
The first clinical trial using Notch-mediated ex vivo expanded cord blood HSPC was initiated by Dr. Delaney in 2006 in the myeloablative double cord blood transplant setting.
Latest scientific publications
Infusion of a non-HLA-matched ex-vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase 1 trial. Lancet Haematol. 2016 Jul;3(7):e330-9. Epub 2016 Jun 7
Cord-Blood Transplantation in Patients with Minimal Residual Disease. N Engl J Med. 2016 Sep 8;375(10):944-53.
Identificationof CD137+ IFN-g- CD4+ Alloreactive T Cells Post Myeloablative Double Cord BloodTransplant: A Synergistic Role in the Graft Versus Graft Interaction. ASBMT AnnualMeeting, San Diego, CA February 2015.
Infusion of ex vivo expanded cord blood progenitor cells is associated with reduced hospital daysand utilization of opiate infusion and total parental nutrition in pediatricpatients receiving myeloablative cord blood transplantation. ASBMT AnnualMeeting, San Diego, CA February 2015.